Topical treatment of neuropathic pain using compounded medications

Clinical Journal of Pain

Volumn 30, Issue 1, 2014, Pages 73-91

  Zur, Eyal ^a  

^a Super Pharm Professional Central Compounding Laboratory   (Israel)

Author keywords

compounding medicines; compounding pharmacist; localized cutaneous NP; NP; peripheral nervous system; topical treatment of NP

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA 2 ADRENERGIC RECEPTOR; AMITRIPTYLINE; BACLOFEN; CALCITONIN GENE RELATED PEPTIDE; CAPSAICIN; CLONAZEPAM; CLONIDINE; CODEINE; DICLOFENAC; DOXEPIN; ETHER; GABAPENTIN; GLUTAMIC ACID; IBUPROFEN; INDOMETACIN; KETAMINE; KETOPROFEN; LIDOCAINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; POLOXAMER; PREGABALIN; PRILOCAINE; SUBSTANCE P; TETRACAINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VANILLOID RECEPTOR 1; VOLTAGE GATED SODIUM CHANNEL;

ABSENCE OF SIDE EFFECTS; ALLODYNIA; APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; APPLICATION SITE PAIN; BACKACHE; BURNING MOUTH SYNDROME; BURNING SENSATION; CANCER PAIN; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; CHRONIC PAIN; COMPLEX REGIONAL PAIN SYNDROME; DIABETIC NEUROPATHY; DROWSINESS; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FOOT PAIN; HEADACHE; HUMAN; HYPERALGESIA; NEPHROTOXICITY; NEUROPATHIC PAIN; NONHUMAN; PAIN ASSESSMENT; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT SATISFACTION; PERIPHERAL NEUROPATHY; PHARMACIST; PHOTOSENSITIVITY; PHOTOTOXICITY; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SKIN ABSORPTION; SKIN IRRITATION; SKIN PERMEABILITY; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TRIGEMINUS NEURALGIA; VESTIBULODYNIA; VULVODYNIA;

ADMINISTRATION, TOPICAL; ANALGESICS; DRUG COMPOUNDING; EVIDENCE-BASED MEDICINE; HUMANS; NEURALGIA;

EID: 84890431098     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e318285d1ba     Document Type: Review

References (116)

1. Jensen TS, Baron R, HaanpääM, et al. A new definition of neuropathic pain. Pain. 2011;152:2204-2205
2. HaanpääM, Backonja MM, Bennett M, et al. Assessment of neuropathic pain in primary care. Am J Med. 2009;122: S13-S21
3. Finnerup NB, Sindrup SH, Jensen TS. The evidence of pharmacological treatment of neuropathic pain. Pain. 2010;150:573-581
4. Galer BS. Topical analgesic medication -The dawn of a new era. Pain. 2009;147:5-6
5. Nicolaou A, Nicholson B, Hans G, et al. Outcome predictors for treatment success with 5% lidocaine medicated plaster in low back pain with neuropathic components and neuropathic pain after surgical and nonsurgical trauma. J Pain Res. 2011;4:25-38
6. Argoff CE. New analgesics for neuropathic pain: The lidocaine patch. Clin J Pain. 2000;16:S62-S66
7. Baron R, Mayoral V, Leijon G, et al. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: An open-label, non-inferiority two-stage RCT study. Curr Med Res Opin. 2009;25:1663-1676
8. Baron R, Mayoral V, Leijon G, et al. Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in postherpetic neuralgia and diabetic polyneuropathy. Curr Med Res Opin. 2009;25:1677-1687
9. Binder A, Bruxelle J, Rogers P, et al. Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: Results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig. 2009;29: 393-408
10. Hans G, Sabatowski R, Binder A, et al. Efficacy and tolerability of a 5% lidocaine medicated plaster for the topical treatment of post-herpetic neuralgia: Results of a longterm study. Curr Med Res Opin. 2009;25:1295-1305
11. Rowbotham MC, Davies PS, Verkempinck C, et al. Lidocaine patch: Double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain. 1996;65:39-44
12. Barbano RL, Herrmann DN, Hart-Gouleau S, et al. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuropathy. Arch Neurol. 2004;61:914-918
13. Herrmann DN, Barbano RL, Hart-Gouleau S, et al. An openlabel study of the lidocaine patch 5% in painful idiopathic sensory polyneuropathy. Pain Med. 2005;6:379-384
14. Nalamachu S, Crockett RS, Gammaitoni AR, et al. A comparison of the lidocaine patch 5% vs naproxen 500 mg twice daily for the relief of pain associated with carpal tunnel syndrome: A 6-week, randomized, parallel-group study. MedGenMed. 2006;8:33
15. Hans G, Joukes E, Verhulst J, et al. Management of neuropathic pain after surgical and non-surgical trauma with lidocaine 5% patches: Study of 40 consecutive cases. Curr Med Res Opin. 2009;25:2737-2743
16. Brabant S, Nagels W. Topical lidocaine 5% patch for the treatment of chronic postsurgical neuropathic skin pain. Pain Pract. 2009;9(S1):35
17. Wolff RF, Bala MM, Wstwood M, et al. 5% Lidocainemedicated plaster VS other relevant interventions and placebo for post-herpetic neuralgia (PHN): A systemic review. Acta Neurol Scand. 2011;123:295-309
18. McCormack PL. Capsaicin dermal patch: In non-diabetic peripheral neuropathic pain. Drugs. 2010;70:1831-1842
19. Anand P, Bley K. Topical capsaicin for pain management: Therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011;107:490-502
20. Jones VM, Moore KA, Peterson DM. Capsaicin 8% topical patch (Qutenza) -A review of the evidence. J Pain Palliat Care Pharmacother. 2011;25:32-41
21. Irving GA, Backonja M, Rauckj R, et al. NGX-4010, a capsaicin 8% dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia. Clin J Pain. 2012;28:101-107
22. Campbell CM, Kipnes MS, Stouch BC, et al. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain. 2012;153:1815-1823
23. McCleane G. Topical application of doxepin hydrochloride, capsaicin and combination of both produces analgesia in chronic human neuropathic pain: A randomized double-blind, placebo-controlled study. Br J Clin Pharmacol. 2000;49: 574-579
24. Benedittis GDe, Lorenzetti A. Topical aspirin/diethyl ether mixture versus indomethacin and diclofenac/diethyl ether mixtures for acute herpetic neuralgia and post herpetic neuralgia: A double-blind crossover placebo-controlled study. Pain. 1996;65:45-51
25. Barton DL, Wos EJ, Qin R, et al. A double-blind, placebocontrolled trial of a topical treatment for chemotherapyinduced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer. 2011;19:833-841
26. Finch PM, Knudsen L. Reduction of allodynia in patients with complex regional pain syndrome: A double-blind placebo-controlled trial of topical ketamine. Pain. 2009;146: 18-25
27. Gremeau-Richard C, Woda A, Navez ML, et al. Topical clonazepam in stomatodynia: A randomized placebocontrolled study. Pain. 2004;108(1-2):51-57
28. Lynch ME, Clark AJ, Sawynok J, et al. Topical amitriptyline and ketamine in neuropathic pain syndromes: An openlabel study. J Pain. 2005;6:644-649
29. Uzaraga I, Gerbis B, Holwerda E, et al. Topical amitriptyline, ketamine, and lidocaine in neuropathic pain caused by radiation skin reaction: A pilot study. Support Care Cancer. 2012;20:1515-1524
30. Boardman LA, Cooper AS, Blais LR, et al. Topical Gabapentin in the treatment of localized and generalized vulvodynia. Obstet Gynecol. 2008;112:579-585
31. Nyirjesy P, Lev-Sagie A, Mathew L, et al. Topical Amitriptyline-Baclofen Cream for the treatment of provoked vestibulodynia. J Low Genit Tract Dis. 2009;13:230-236
32. Heir G, Karolehek S, Kalladka M, et al. Use of topical medication in orofacial neuropathic pain; a retrospective study. Surg Oral Med Oral Pathol Endod. 2008;105:466-469
33. Boulais N, Misery L. The epidermis: A sensory tissue. Eur J Dermatol. 2008;18:119-127
34. Irving G. The role of the skin in peripheral neuropathic pain. Eur J Pain Suppl. 2010;4:157-160
35. Radtke C, Vogt PM, Devor M, et al. Keratinocytes acting on injured afferents induce extreme neuronal hyperexcitability and chronic pain. Pain. 2010;148:94-102
36. Zhao P, Barr TP, Hou Q, et al. Voltage-gated sodium channel expression in rat and human epidermal keratinocytes: Evidence for a role in pain. Pain. 2008;139:90-105
37. Hou Q, Barr T, Gee L, et al. Keratinocyte expression of calcitonine gene related peptide b: Implications for neuropathic and inflammatory pain mechanisms. Pain. 2011;152:2036-2051
38. Lumpkin EA, Caterina MJ. Mechanisms of sensory transduction in the skin. Nature. 2007;445:858-865
39. Cairns BE. Peripheral Receptor Targets for Analgesia: Novel Approaches to Pain Management. New Jersey: Wiley ISBN 978-0-470-25131-7; 2009
40. Sawynok J. Topical and peripherally acting analgesics. Pharmacol Rev. 2003;55:1-20
41. Carlton SM. Peripheral NMDA receptors revisited-hope floats. Pain. 2009;146:1-2
42. Carlton SM, Coggeshall RE. Nociceptive integration: Does it have a peripheral component? Pain Forum. 1998;7:71-78
43. Stein C, Clark JD, Oh U, et al. Peripheral mechanisms of pain and analgesia. Brain Res Rev. 2009;60:90-113
44. Lynch ME, Craig KD, Peng PWH. Clinical Pain Management: A Practical Guide. Chapter 17: Sawynok J. Topical analgesics. New Jersey: Blackwell Publishing; 2011: 135-141
45. Mick G, Baron R, Finnerup NB, et al. What is localized neuropathic pain? A first proposal to characterize and define a widely used term. Pain Manag. 2012;2:71-77
46. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: Evidence-based recommendations. Pain. 2007;132:237-251
47. Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain: Consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag. 2007;12:13-21
48. Campbell JN. How does topical lidocaine relieve pain. Pain. 2012;153:255-256
49. Scholz J, Woolf CJ. The neuropathic pain triad: Neurons, immune cells and glia. Nat Neurosci. 2007;10:1361-1368
50. Thacker MA, Clark AK, Marchand F, et al. Pathophysiology of peripheral neuropathic pain: Immune cells and molecules. Anesth Analg. 2007;105:838-847
51. Cairns BE, Prateepavanich P. Role of peripheral mechanisms in spinal pain conditions. In: Cairns BE, ed. Peripheral Receptor Targets for Analgesia. Novel Approaches to Pain Management. New Jersey: Wiley; 2009:21-40
52. Devor M. Ectopic discharge in Ab afferents as a source of neuropathic pain. Exp Brain Res. 2009;196:115-128
53. Krumova EK, Zeller M, Westermann A, et al. Lidocaine patch (5%) produces a selective, but incomplete block of Ad and C fibers. Pain. 2012;153:273-280
54. Kinkelin I, Brocker EB, Koltzenburg M, et al. Localization of ionotropic glutamate receptors in peripheral axons of human skin. Neurosci Lett. 2000;2832:149-152
55. Warncke T, Jorum E, Stubhaug A. Local treatment with the N-methyl-D-aspartate receptor antagonist ketamine, inhibit development of secondary hyperalgesia in man by a peripheral action. Neurosci Lett. 1977;2271:1-4
56. Davis KD, Treede RD, Raja SN, et al. Topical application of clonidine relieves hyperalgesia in patients with sympathetically maintained pain. Pain. 1991;47:309-317
57. Miller KE, Hoffman EM, Sutharshan M, et al. Glutamate pharmacology and metabolism in peripheral primary afferents: Physiological and pathophysiological mechanisms. Pharmacol Ther. 2011;130:283-309
58. Ambalavanar R, Dessem D. Calcitonin gene-related peptide and substance P. In: Cairns BE, ed. Peripheral Receptor Targets For Analgesia. Novel Approaches To Pain Management. New Jersey: Wiley; 2009:373-396
59. Lynch ME, Clark AJ, Sawynok J, et al. Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes: A randomized, double-blind, placebo-controlled trial. Anesthesiology. 2005;103:140-146
60. Mahoney JM, Vardaxis V, Moore JL, et al. Topical ketamine cream in the treatment of painful diabetic neuropathy a randomized, placebo-controlled, double-blind initial study. J Am Podiatr Med Assoc. 2012;102:178-183
61. Ho KY, Huh BK, White WD, et al. Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. Clin J Pain. 2008;24:51-55
62. Bareggi SR, Pirola R, Benedittis GDe. Skin and plasma levels of acetylsalicylic acid: A comparison between topical aspirin/ diethyl ether mixture and oral aspirin in acute herpes zoster and postherpetic neuralgia. Eur J Clin Pharmacol. 1998;54:231-235
63. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: An overview and literature update. Mayo Clin Proc. 2010;85(suppl 3):S3-S14
64. Mao J, Gold MS, Backonja M. Combination drug therapy for chronic pain: A call for more clinical studies. J Pain. 2011;12:157-166
65. Tracy JA, Dyck PJ. The spectrum of diabetic neuropathies. Phys Med Rehabil Clin N Am. 2008;19:1-26
66. Wolf SL, Barton DL, Qin R, et al. The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, NO6CA. Support Care Cancer. 2012;20:625-632
67. Oaklander AL, Fields HL. Is reflex sympathetic dystrophy/ complex regional pain syndrome type I a small-fiber neuropathy? Ann Neurol. 2009;65:629-638
68. Zur E. Burning mouth syndrome: A discussion of a complex pathology. Int J Pharm Compd. 2012;16:196-205
69. Jääskeläinen SK. Pathophysiology of primary burning mouth syndrome. Clinical. Neurophysiology. 2012;123:71-77
70. Woda A, Navez M, Picard P, et al. A possible therapeutic solution for stomatodynia (burning mouth syndrome). J Orofac Pain. 1998;12:1-6
71. Kamoun P, Frejaville JP. Guide des Examens de Laboratoire. Paris: Flammarion; 1993
72. Sessle BJ. Role of peripheral mechanisms in craniofacial pain conditions. In: Cairns BE, ed. Peripheral Receptor Targets for Analgesia. Novel Approaches to Pain Management. New Jersey: Wiley; 2009:3-20
73. Haroutinian S, Drennan DA, Lipman AG. Topical NSAID therapy for musculoskeletal pain. Pain Med. 2010;11: 535-549
74. Villegas FP, Heir G, Markman S, et al. Topical pregabalin and diclofenac for the treatment of neuropathic orofacial pain in rats. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114:449-456
75. Brown S, Erickson B, Muller G. Compounded analgesic therapy for disorders of movement: Arthritis, neuropathic pain, and postpolio syndrome. Int J Pharm Compd. 2010; 14:182-192
76. Bramwell BL. Topical medications for orofacial neuropathic pain. Int J Pharm Compd. 2010;14:200-203
77. Vadaurri V. Topical treatment of neuropathic pain. Int J Pharm Compd. 2008;12:183-190
78. McNulty JP, Muller G. Update on managing neuropathic pain. Int J Pharm Compd. 2009;13:182-190
79. Williams KD. Managing pain with transdermal ketoprofen. Int J Pharm Compd. 2010;14:204-206
80. Almeida H, Amaral MH, Lobäo P, et al. Pluronic F-127 and pluronic lecithin organogel (PLO): Main features and their applications in topical and transdermal administration of drugs. J Pharm Pharm Sci. 2012;15:592 -605
81. Schubert MC, Sridhar S, Schade RR, et al. What every gastroenterologist needs to know about common anorectal disorders. World J Gastroenterol. 2009;15:3201-3209
82. Lefaucheur JP, Labat JJ, Amarenco G, et al. What is the place of electroneuromyographic studies in the diagnosis and management of pudendal neuralgia related to entrapment syndrome? Clin Neurophysiol. 2007;37:223-228
83. Stav K, Dwyer PL, Roberts L. Pudendal neuralgia fact or fiction? Obstet Gynecol Surv. 2009;64:190-199
84. Tu FF, Hellman KM, Backonja MM. Gynecologic management of neuropathic pain. Am J Obstet Gynecol. 2011; 435-443
85. Labat JJ, Riant T, Robert R, et al. Diagnostic criteria for pudendal neuralgia by pudendal nerve entrapment (Nantes criteria). Neurourol Urodyn. 2008;27:306-310
86. Baroli B. Penetration of nanoparticles and nanomaterials in the skin: Fiction or reality? J Pharm Sci. 2010;99:21-50
87. Bos JD, Meinardi MMHM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000;9:165-169
88. Kopsky DJ, Keppel Hesselink JM. High doses of topical amitriptyline in neuropathic pain: Two cases and literature review. Pain Pract. 2012;12:148-153
89. Sandroni P, Davis DP. Combination gel of 1% amitriptyline and 0.5% ketamine to treat refractory erythromelalgia pain. a new treatment option? Arch Dermatol. 2006;142: 283-286
90. Gammaitoni A, Gallagher RM, Welz-Bosana M. Topical ketamine gel: Possible role in treating neuropathic pain. Pain Med. 2000;1:97-100
91. Prommer EE. Topical analgesic combinations for bortezomib neuropathy. J Pain Symptom Manage. 2009;37:e3-e5
92. Liebregts R, Kopsky DJ, Keppel Hesselink JM. Topical amitriptyline in post-traumatic neuropathic pain. J Pain Symptom Manage. 2011;41:e6-e7
93. Kopsky DJ, Keppel Hesselink JM. A new combination cream for the treatment of severe neuropathic pain. J Pain Symptom Manage. 2010;39:e9-e10
94. Trommer H, Neubert RHH. Overcoming the stratum corneum: The modulation of skin penetration. Skin Pharmacol Physiol. 2006;19:106-121
95. Barry BW. Breaching the skin's barrier to drugs. Nat Biotechnol. 2004;22:165-167
96. European commission health & consumer protection directorate-general. Directorate E. guidance document on dermatology absorption. Sanco/222/2000 Rev 7 March 19, 2004: 1-15 [European Commission Website]. Available at: Http:// ec.europa.eu/food/plant/protection/evaluation/guidance/ wrkdoc20-rev-en.pdf. Accessed January 15, 2011
97. Häfeli UO, Kale A. Topical and systemic drug delivery systems for targeted therapy. In: Cairns BE, ed. Peripheral Receptor Targets for Analgesia. Novel Approaches to Pain Management. New Jersey: Wiley; 2009:475-514
98. Logović L, Š itum M, Ož anić -Bulić S, et al. Phototoxic and photoallergic skin reactions. Coll Antropol. 2007;31:63-67
99. Heilmann S, Küchler SV, Schäfer-Korting M. Morphine metabolism in human skin microsomes. Skin Pharmacol Physiol. 2012;25:319-322
100. Oni G, Brown S, Burrus C, et al. Effect of 4% topical lidocaine applied to the face on the serum levels of lidocaine and its metabolite, monoethylglycinexylidide. Aesthetic Surg J. 2010;30:853-858
101. Rolsted K, Benfeldt E, Kissmeyer AM, et al. Cutaneous in vivo metabolism of topical lidocaine formulation in human skin. Skin Pharmacol Physiol. 2009;22:124-127
102. Ness TJ, Jones L, Smith H. Use of compounded topical analgesics-results of an internet survey. Region Anesth Pain Med. 2002;27:309-312
103. The United States pharmacopeia 34. /795S Pharmaceutical compounding -none sterile preparations. 2011. Available at: Http://forums.pharmacyonesource.com/ phos/attachments/phos/ pharmacy-ops/883/1/USP%2034-795.pdf
104. The United States pharmacopeia 34. /797S Pharmaceutical compounding -sterile preparations. 2011. Available at: Http://www.pbm.va.gov/ LinksAndOtherResources/USP%207 97%20Pharmaceutical%20Compounding%20- %20Sterile%20 Compounding.pdf
105. Pharmacy compounding accreditation board (PCAB) website. Available at: Http://www.pcab.org/.
106. International Journal of Pharmaceutical Compounding (IJPC) website. Available at: Http://www.ijpc.com/.
107. Compounding today website. Available at: Http:// compoundingtoday.com/ index.cfm
108. Allen LV. The Art, Science, And Technology Of Pharmaceutical Compounding. Washington DC: American Pharmaceutical Association publication; 2002
109. Allen LV. Suppositories. London, Chicago: Pharmaceutical Press publication; 2008
110. Allen LV. Allen's Compounded Formulations: The Complete U. S. Pharmacist Collection. Washington DC: American Pharmaceutical Association; 2003
111. Secundum Artem-Free compounding knowledge as continuing education at Perigo Pharmaceuticals website (formerly Paddock Laboratories). Available at: Http://www.perrigo. com/search.aspx?term=secundum%20artem
112. Allen LV. Basics of compounding: Implementing United States pharmacopeia chapter <1163> quality assurance in pharmaceutical compounding, part 1. Int J Pharm Compd. 2012;16:146-150
113. Cabaleiro J. Quality-control analytical methods: Quality control, quality assurance, and quality improvement-what is the difference and why should compounding pharmacies care? Int J Pharm Compd. 2009;13:318-320
114. Allen LV. Basics of compounding: Implementing United States pharmacopeia chapter <1163> quality assurance in pharmaceutical compounding, part 3: Testing. Int J Pharm Compd. 2012;16:322-328
115. Kainer MA, Reagan DR, Nguyen DB, et al. Fungal infections associated with contaminated methylprednisolone in Tennessee. N Engl J Med. 2012;367:2194-2203
116. Allen LV. Letter from the editor. Editorial: Compounding pharmacistsythank you! Compounding Today website. 2012; 9 (41). Available at: Http://compoundingtoday.com/ Newsletter/Newsletter9-41.cfm